Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott, Liquidia to develop siRNA therapeutics

This article was originally published in Clinica

Executive Summary

Liquidia Technologies is set to develop its Print nanoparticle technology for the delivery of siRNA-based therapeutics alongside Abbott Laboratories, after the two firms signed a collaboration and licence agreement. The partnership will see Liquidia (Research Triangle Park, North Carolina) provide Abbott with certain rights to its Print technology, in order to develop and commercialise more targeted, safer and effective siRNA therapeutics for cancer patients. According to Liquidia, the Print technology can achieve this by making nanoparticles with customised size, shape, surface chemistry and composition. Financial terms of the deal were not revealed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042315

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel